2,6-二苯甲氧基苯甲腈 | 94088-47-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2,6-二苯甲氧基苯甲腈
• 中文别名: 2,6-二苄氧基苯甲腈
• 英文名称: 2,6-dibenzyloxybenzonitrile
• 英文别名: 2,6-benzyloxybenzonitrile；2,6-bis(phenylmethoxy)benzonitrile
• CAS: 94088-47-8
• 化学式: C₂₁H₁₇NO₂
• mdl: MFCD00016874
• 分子量: 315.371
• InChiKey: VMVKBYOKFOFDOD-UHFFFAOYSA-N

物化性质

• 熔点：
  122-124°C
• 沸点：
  514.4±40.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  常温常压下稳定，避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.095
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S22,S24/25
• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  2,6-二苯甲氧基苯甲腈 在 palladium on activated charcoal 、 四丁基溴化铵 、 氢气 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 1,2-二氯乙烷 、 苯甲醇 为溶剂， 反应 42.0h， 生成 1-(fluoren-9-yl)-3-(2,6-dihydroxybenzoyl)urea
  参考文献：
  名称：

  抗丙型肝炎病毒化合物及其制备方法和应用

  摘要：

  本发明提出了一种抗丙型肝炎病毒化合物及其制备方法和应用。该化合物为式1所示化合物或式1所示化合物的立体异构体、几何异构体、互变异构体，其中，R1和R2分别独立地选自氢、甲酰基、苯甲酰基以及C1-C3直链或支链烷基，并且R1和R2不同时为氢。该化合物具有较好的脂溶性和理化性质，从而可以显著提高生物利用度和体内药效。

  公开号：

  CN104058996B
• 作为产物：
  描述：

  2,6-二氟苯腈 、 potassium benzyloxide 以 二甲基亚砜 为溶剂， 以50%的产率得到2,6-二苯甲氧基苯甲腈
  参考文献：
  名称：

  Discovering Potent Small Molecule Inhibitors of Cyclophilin A Using de Novo Drug Design Approach

  摘要：

  This work describes an integrated approach of de novo drug design, chemical synthesis, and bioassay for quick identification of a series of novel small molecule cyclophilin A (CypA) inhibitors (1-3). The activities or the two most potent CypA inhibitors (3h and 3i) are 2.59 and 1.52 nM, respectively, which are about 16 and 27 times more potent than that of cyclosporin A. This study clearly demonstrates the power of our de novo drug design strategy and the related program LigBuilder 2.0 in drug discovery.

  DOI：

  10.1021/jm9008295

文献信息

• [EN] PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSES DE PYRIMIDINE UTILES POUR LE TRAITEMENT DES INFLAMMATIONS
  申请人：PHARMACIA CORP

  公开号：WO2005040133A1

  公开（公告）日：2005-05-06

  Compounds of Formula (I): wherein A, X, R2 and R4 are as defined herein, are disclosed.

  式(I)的化合物：其中A、X、R2和R4如本文所定义，已被披露。
• Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition
  作者：Wenzhong Yan、Jie Qing、Hanbing Mei、Junxiu Nong、Jin Huang、Jin Zhu、Hualiang Jiang、Lei Liu、Linqi Zhang、Jian Li

  DOI：10.1016/j.bmcl.2015.11.002

  日期：2015.12

  In this work, the relationship between cyclophilin A (CypA) and EV71 prompted us to screen a series of small molecular CypA inhibitors which were previously reported by our group. Among them, compounds 1 and 2 were discovered as non-immunosuppressive anti-EV71 agents with an EC50 values of 1.07 +/- 0.17 mu M and 3.36 +/- 0.45 mu M in virus assay, respectively, which were desirably for the further study. The subsequent chemical modifications derived a novel class of molecules, among which compound 11 demonstrated the most potent anti-EV71 activity in virus assay (EC50 = 0.37 +/- 0.17 mu M), and low cytotoxicity (CC50 > 25 mu M). The following CypA enzyme inhibition studies indicated that there was not only the enzyme inhibition activity, undoubtedly important, functioning in the antiviral process, but also some unknown mechanisms worked in combination, and the further study is underway in our laboratory. Nevertheless, to the best of our knowledge, compound 11 was probably the most potent small molecular anti-EV71 agent via CypA inhibitory mechanism to date. Consequently, our study provided a new potential small molecule for curing EV71 infection. (C) 2015 Elsevier Ltd. All rights reserved.
• PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION
  申请人：Pharmacia Corporation

  公开号：EP1678146A1

  公开（公告）日：2006-07-12
• [EN] BALANOIDS<br/>[FR] BALANOIDES
  申请人：——

  公开号：WO1994020062A2

  公开（公告）日：1994-09-15

  [EN] A novel class of therapeutic compounds, denominated Balanoids, is disclosed. Balanoids have protein kinase C inhibitory activity and selectivity among the isoforms of protein kinase C. Balanoids are useful for treatment of diseases related to protein kinase C in animals, especially humans and is especially indicated for treatment of inflammatory diseases.
  [FR] Nouvelle classe de composés thérapeutiques nommés balanoïdes. Lesdits composés possèdent une activité inhibitrice de la protéine kinase C et une sélectivité parmi les isoformes de la protéine kinase C. Les balanoïdes sont utiles pour traiter les maladies liées à la protéine kinase C chez les animaux, en particulier chez leshumains, et ils sont particulièrement indiqués pour traiter les maladies inflammatoires.
• Discovering Potent Small Molecule Inhibitors of Cyclophilin A Using de Novo Drug Design Approach
  作者：Shuaishuai Ni、Yaxia Yuan、Jin Huang、Xiaona Mao、Maosheng Lv、Jin Zhu、Xu Shen、Jianfeng Pei、Luhua Lai、Hualiang Jiang、Jian Li

  DOI：10.1021/jm9008295

  日期：2009.9.10

  This work describes an integrated approach of de novo drug design, chemical synthesis, and bioassay for quick identification of a series of novel small molecule cyclophilin A (CypA) inhibitors (1-3). The activities or the two most potent CypA inhibitors (3h and 3i) are 2.59 and 1.52 nM, respectively, which are about 16 and 27 times more potent than that of cyclosporin A. This study clearly demonstrates the power of our de novo drug design strategy and the related program LigBuilder 2.0 in drug discovery.